[{"model": "coag.coag", "pk": 1, "fields": {"drugName": "Abciximab", "nx_hold_b_p": "Avoid until normal platelet function has recovered.", "nx_restart_a_p": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitate assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued antithrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "nx_hold_b_c": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitate assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued antithrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "nx_restart_a_c": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitate assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued antithrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "db_hold_b_p": "Avoid until normal platelet function has recovered.", "db_restart_a_p": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitate assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued antithrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitate assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued antithrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "Avoid until normal platelet function has recovered.", "ap_restart_a_p": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitate assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued antithrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitate assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued antithrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal."}}, {"model": "coag.coag", "pk": 2, "fields": {"drugName": "Apixaban", "nx_hold_b_p": "72hrs.\r\nWe suggest that the drug to be discontinued 72hrs prior to neuraxial block. Consider checking the drug or anti-factor Xa activity level if less than 72hrs. An acceptable level of residual apixaban activity to proceed with neuraxial block remains undetermined.", "nx_restart_a_p": "At least 6hrs, AVOID with indwelling catheters.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "nx_hold_b_c": "26-30hrs or anti-factor Xa assay", "nx_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "db_hold_b_p": "72hrs.\r\nWe suggest that the drug to be discontinued 72hrs prior to neuraxial block. Consider checking the drug or anti-factor Xa activity level if less than 72hrs. An acceptable level of residual apixaban activity to proceed with neuraxial block remains undetermined.", "db_restart_a_p": "At least 6hrs, AVOID with indwelling catheters.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "db_hold_b_c": "26-30hrs or anti-factor Xa assay.", "db_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "72hrs.\r\nWe suggest that the drug to be discontinued 72hrs prior to neuraxial block. Consider checking the drug or anti-factor Xa activity level if less than 72hrs. An acceptable level of residual apixaban activity to proceed with neuraxial block remains undetermined.", "ap_restart_a_p": "At least 6hrs, AVOID with indwelling catheters.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "ap_hold_b_c": "26-30hrs or anti-factor Xa assay.", "ap_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose."}}, {"model": "coag.coag", "pk": 3, "fields": {"drugName": "Argatroban", "nx_hold_b_p": "AVOID.\r\nNeuraxial technique not recommended.", "nx_restart_a_p": "AVOID.\r\nNeuraxial technique not recommended.", "nx_hold_b_c": "AVOID.", "nx_restart_a_c": "AVOID.\r\nNeuraxial technique not recommended.", "db_hold_b_p": "AVOID.\r\nNeuraxial technique not recommended.", "db_restart_a_p": "AVOID.\r\nNeuraxial technique not recommended.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "AVOID.\r\nNeuraxial technique not recommended.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "AVOID.\r\nNeuraxial technique not recommended.", "ap_restart_a_p": "AVOID.\r\nNeuraxial technique not recommended.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "AVOID.\r\nNeuraxial technique not recommended."}}, {"model": "coag.coag", "pk": 4, "fields": {"drugName": "Aspirin", "nx_hold_b_p": "No restrictions.\r\nIn patients receiving NSAIDs, we suggest caution in the performance of neuraxial techniques if the concurrent use of other medications affecting clotting mechanisms, such as other anti-platelet agents, oral anti-coagulants, UFH, and LMWH, is anticipated in the early postoperative period because of the increased risk of bleeding complications.", "nx_restart_a_p": "No restrictions.\r\nIn patients receiving NSAIDs, we suggest caution in the performance of neuraxial techniques if the concurrent use of other medications affecting clotting mechanisms, such as other anti-platelet agents, oral anti-coagulants, UFH, and LMWH, is anticipated in the early postoperative period because of the increased risk of bleeding complications.", "nx_hold_b_c": "No restrictions.", "nx_restart_a_c": "No restrictions.\r\nIn patients receiving NSAIDs, we suggest caution in the performance of neuraxial techniques if the concurrent use of other medications affecting clotting mechanisms, such as other anti-platelet agents, oral anti-coagulants, UFH, and LMWH, is anticipated in the early postoperative period because of the increased risk of bleeding complications.", "db_hold_b_p": "No restrictions.\r\nIn patients receiving NSAIDs, we suggest caution in the performance of neuraxial techniques if the concurrent use of other medications affecting clotting mechanisms, such as other anti-platelet agents, oral anti-coagulants, UFH, and LMWH, is anticipated in the early postoperative period because of the increased risk of bleeding complications.", "db_restart_a_p": "No restrictions.\r\nIn patients receiving NSAIDs, we suggest caution in the performance of neuraxial techniques if the concurrent use of other medications affecting clotting mechanisms, such as other anti-platelet agents, oral anti-coagulants, UFH, and LMWH, is anticipated in the early postoperative period because of the increased risk of bleeding complications.", "db_hold_b_c": "No restrictions.", "db_restart_a_c": "No restrictions.\r\nIn patients receiving NSAIDs, we suggest caution in the performance of neuraxial techniques if the concurrent use of other medications affecting clotting mechanisms, such as other anti-platelet agents, oral anti-coagulants, UFH, and LMWH, is anticipated in the early postoperative period because of the increased risk of bleeding complications.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "No restrictions.\r\nIn patients receiving NSAIDs, we suggest caution in the performance of neuraxial techniques if the concurrent use of other medications affecting clotting mechanisms, such as other anti-platelet agents, oral anti-coagulants, UFH, and LMWH, is anticipated in the early postoperative period because of the increased risk of bleeding complications.", "ap_restart_a_p": "No restrictions.\r\nIn patients receiving NSAIDs, we suggest caution in the performance of neuraxial techniques if the concurrent use of other medications affecting clotting mechanisms, such as other anti-platelet agents, oral anti-coagulants, UFH, and LMWH, is anticipated in the early postoperative period because of the increased risk of bleeding complications.", "ap_hold_b_c": "No restrictions.", "ap_restart_a_c": "No restrictions.\r\nIn patients receiving NSAIDs, we suggest caution in the performance of neuraxial techniques if the concurrent use of other medications affecting clotting mechanisms, such as other anti-platelet agents, oral anti-coagulants, UFH, and LMWH, is anticipated in the early postoperative period because of the increased risk of bleeding complications."}}, {"model": "coag.coag", "pk": 5, "fields": {"drugName": "Betrixaban", "nx_hold_b_p": "3days.\r\nWe suggest that the drug be discontinued a minimum of 3 days prior to neuraxial block. Consider checking the drug level or anti-factor Xa level if less than 3 days.", "nx_restart_a_p": "At least 5hrs, AVOID with indwelling catheters.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 5hrs prior to the first dose.", "nx_hold_b_c": "72hrs.", "nx_restart_a_c": "5hrs.\r\nWe suggest that neuraxial catheters 5hrs be removed prior to next dose.", "db_hold_b_p": "3days.\r\nWe suggest that the drug be discontinued a minimum of 3 days prior to neuraxial block. Consider checking the drug level or anti-factor Xa level if less than 3 days.", "db_restart_a_p": "At least 5hrs, AVOID with indwelling catheters.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 5hrs prior to the first dose.", "db_hold_b_c": "72hrs.", "db_restart_a_c": "5hrs.\r\nWe suggest that neuraxial catheters 5hrs be removed prior to next dose.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "3days.\r\nWe suggest that the drug be discontinued a minimum of 3 days prior to neuraxial block. Consider checking the drug level or anti-factor Xa level if less than 3 days.", "ap_restart_a_p": "At least 5hrs, AVOID with indwelling catheters.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 5hrs prior to the first dose.", "ap_hold_b_c": "72hrs.", "ap_restart_a_c": "5hrs.\r\nWe suggest that neuraxial catheters 5hrs be removed prior to next dose."}}, {"model": "coag.coag", "pk": 6, "fields": {"drugName": "Bivalirudin", "nx_hold_b_p": "AVOID.\r\nNeuraxial technique not recommended.", "nx_restart_a_p": "AVOID.\r\nNeuraxial technique not recommended.", "nx_hold_b_c": "AVOID.", "nx_restart_a_c": "AVOID.\r\nNeuraxial technique not recommended.", "db_hold_b_p": "AVOID.\r\nNeuraxial technique not recommended.", "db_restart_a_p": "AVOID.\r\nNeuraxial technique not recommended.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "AVOID.\r\nNeuraxial technique not recommended.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "AVOID.\r\nNeuraxial technique not recommended.", "ap_restart_a_p": "AVOID.\r\nNeuraxial technique not recommended.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "AVOID.\r\nNeuraxial technique not recommended."}}, {"model": "coag.coag", "pk": 7, "fields": {"drugName": "Cangrelor", "nx_hold_b_p": "Minimum 3hrs.", "nx_restart_a_p": "8rhs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "nx_hold_b_c": "AVOID.", "nx_restart_a_c": "8rhs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "db_hold_b_p": "Minimum 3hrs.", "db_restart_a_p": "8rhs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "8rhs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "Minimum 3hrs.", "ap_restart_a_p": "8rhs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "8rhs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal."}}, {"model": "coag.coag", "pk": 8, "fields": {"drugName": "Cilostazol", "nx_hold_b_p": "2days.\r\nBased on the elimination of half-life, we suggest that neuraxial techniques be avoided for 2days after discontinuation of this drug.", "nx_restart_a_p": "6hrs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "nx_hold_b_c": "AVOID.", "nx_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "db_hold_b_p": "2days.\r\nBased on the elimination of half-life, we suggest that neuraxial techniques be avoided for 2days after discontinuation of this drug.", "db_restart_a_p": "6hrs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "2days.\r\nBased on the elimination of half-life, we suggest that neuraxial techniques be avoided for 2days after discontinuation of this drug.", "ap_restart_a_p": "6hrs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal."}}, {"model": "coag.coag", "pk": 9, "fields": {"drugName": "Clopidogrel", "nx_hold_b_p": "5-7days.", "nx_restart_a_p": "Immediately, if no loading dose & 24hrs postop.\r\nIn accordance with ACCP recommendations, thienopyridine therapy may be re-instituted 24hrs postoperatively.\r\nIf a loading dose is administered, we suggest a time interval of 6hrs between needle placement and administration.\r\nBecause the antiplatelet effect is not immediate with ticlopidine and clopidogrel, neuraxial catheters may be maintained for 1~2days, provided a loading dose of the anti-platelet agent is not administered.", "nx_hold_b_c": "No information.", "nx_restart_a_c": "Immediately, if no loading dose.\r\nIf a loading dose is administered, we suggest a time interval of 6hrs between needle placement and administration.", "db_hold_b_p": "5-7days.", "db_restart_a_p": "Immediately, if no loading dose & 24hrs postop.\r\nIn accordance with ACCP recommendations, thienopyridine therapy may be re-instituted 24hrs postoperatively.\r\nIf a loading dose is administered, we suggest a time interval of 6hrs between needle placement and administration.\r\nBecause the antiplatelet effect is not immediate with ticlopidine and clopidogrel, neuraxial catheters may be maintained for 1~2days, provided a loading dose of the anti-platelet agent is not administered.", "db_hold_b_c": "No information.", "db_restart_a_c": "Immediately, if no loading dose.\r\nIf a loading dose is administered, we suggest a time interval of 6hrs between needle placement and administration.", "sp_hold_b_p": "No information.", "sp_restart_a_p": "Immediately, if no loading dose & 24hrs postop.\r\nIn accordance with ACCP recommendations, thienopyridine therapy may be re-instituted 24hrs postoperatively.\r\nIf a loading dose is administered, we suggest a time interval of 6hrs between needle placement and administration.\r\nBecause the antiplatelet effect is not immediate with ticlopidine and clopidogrel, neuraxial catheters may be maintained for 1~2days, provided a loading dose of the anti-platelet agent is not administered.", "sp_hold_b_c": "No information.", "sp_restart_a_c": "Immediately, if no loading dose.\r\nIf a loading dose is administered, we suggest a time interval of 6hrs between needle placement and administration.", "ap_hold_b_p": "5-7days.", "ap_restart_a_p": "Immediately, if no loading dose & 24hrs postop.\r\nIn accordance with ACCP recommendations, thienopyridine therapy may be re-instituted 24hrs postoperatively.\r\nIf a loading dose is administered, we suggest a time interval of 6hrs between needle placement and administration.\r\nBecause the antiplatelet effect is not immediate with ticlopidine and clopidogrel, neuraxial catheters may be maintained for 1~2days, provided a loading dose of the anti-platelet agent is not administered.", "ap_hold_b_c": "No information.", "ap_restart_a_c": "Immediately, if no loading dose.\r\nIf a loading dose is administered, we suggest a time interval of 6hrs between needle placement and administration."}}, {"model": "coag.coag", "pk": 10, "fields": {"drugName": "Dabigatran", "nx_hold_b_p": "120hrs.\r\nWe suggest that dabigatran be discontinued 120hrs prior to neuraxial block. However, if renal function has been reliably determined, and there are no additional risk factors for bleeding, a more graded approach may be considered.\r\nWe suggest that dabigatran be discontinued 72hrs in patients with a CrCl 80ml/min or greater. Consider checking dTT or ecarin clotting time(ECT) if less than 72hrs. An acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined.\r\nWe suggest that dabigatran be discontinued 96hrs in patients with a CrCl 50~79ml/min or greater. Consider checking dTT or ecarin clotting time(ECT) if less than 96hrs. An acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined.\r\nWe suggest that dabigatran be discontinued 120hrs in patients with a CrCl 30~49ml/min or greater. Consider checking dTT or ecarin clotting time(ECT) if less than 120hrs. An acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined.\r\nWe suggest against the performance of neuraxial blocks in CrCl<30ml/min.", "nx_restart_a_p": "6hrs.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "nx_hold_b_c": "34-36hrs or dTT/ECT testing.", "nx_restart_a_c": "6hrs.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "db_hold_b_p": "120hrs.\r\nWe suggest that dabigatran be discontinued 120hrs prior to neuraxial block. However, if renal function has been reliably determined, and there are no additional risk factors for bleeding, a more graded approach may be considered.\r\nWe suggest that dabigatran be discontinued 72hrs in patients with a CrCl 80ml/min or greater. Consider checking dTT or ecarin clotting time(ECT) if less than 72hrs. An acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined.\r\nWe suggest that dabigatran be discontinued 96hrs in patients with a CrCl 50~79ml/min or greater. Consider checking dTT or ecarin clotting time(ECT) if less than 96hrs. An acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined.\r\nWe suggest that dabigatran be discontinued 120hrs in patients with a CrCl 30~49ml/min or greater. Consider checking dTT or ecarin clotting time(ECT) if less than 120hrs. An acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined.\r\nWe suggest against the performance of neuraxial blocks in CrCl<30ml/min.", "db_restart_a_p": "6hrs.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "db_hold_b_c": "34-36hrs or dTT/ECT testing.", "db_restart_a_c": "6hrs.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "120hrs.\r\nWe suggest that dabigatran be discontinued 120hrs prior to neuraxial block. However, if renal function has been reliably determined, and there are no additional risk factors for bleeding, a more graded approach may be considered.\r\nWe suggest that dabigatran be discontinued 72hrs in patients with a CrCl 80ml/min or greater. Consider checking dTT or ecarin clotting time(ECT) if less than 72hrs. An acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined.\r\nWe suggest that dabigatran be discontinued 96hrs in patients with a CrCl 50~79ml/min or greater. Consider checking dTT or ecarin clotting time(ECT) if less than 96hrs. An acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined.\r\nWe suggest that dabigatran be discontinued 120hrs in patients with a CrCl 30~49ml/min or greater. Consider checking dTT or ecarin clotting time(ECT) if less than 120hrs. An acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined.\r\nWe suggest against the performance of neuraxial blocks in CrCl<30ml/min.", "ap_restart_a_p": "6hrs.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "ap_hold_b_c": "34-36hrs or dTT/ECT testing.", "ap_restart_a_c": "6hrs.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose."}}, {"model": "coag.coag", "pk": 11, "fields": {"drugName": "Dalteparin(prophylaxis)", "nx_hold_b_p": "12hrs.\r\nWe recommend that needle placement should occur at least 12hrs after a prophylactic LMWH dose.\r\nIn patients administered a dose of LMWH 2hrs preoperatively, we recommend against neuraxial techniques because needle placement would occur close to peak anti-coagulant activity.", "nx_restart_a_p": "First dose 12hrs.\r\nWe recommend the first postoperative LMWH dose should be administered at least 12hrs after needle/catheter placement. The second postoperative dose should occur no sooner than 24hrs after the first dose.\r\nIndwelling neuraxial catheters do not represent increased risk and may be maintained. However, no additional hemostasis altering medications should be administered because of the additive effects.", "nx_hold_b_c": "12hrs.", "nx_restart_a_c": "At least 4hrs.\r\nAdministration of LMWH should be delayed for 4hrs after catheter removal. We recommend the first dose of LMWH should be administered no earlier than 12hrs after needle/catheter placement.", "db_hold_b_p": "12hrs.\r\nWe recommend that needle placement should occur at least 12hrs after a prophylactic LMWH dose.\r\nIn patients administered a dose of LMWH 2hrs preoperatively, we recommend against neuraxial techniques because needle placement would occur close to peak anti-coagulant activity.", "db_restart_a_p": "First dose 12hrs.\r\nWe recommend the first postoperative LMWH dose should be administered at least 12hrs after needle/catheter placement. The second postoperative dose should occur no sooner than 24hrs after the first dose.\r\nIndwelling neuraxial catheters do not represent increased risk and may be maintained. However, no additional hemostasis altering medications should be administered because of the additive effects.", "db_hold_b_c": "12hrs.", "db_restart_a_c": "At least 4hrs.\r\nAdministration of LMWH should be delayed for 4hrs after catheter removal. We recommend the first dose of LMWH should be administered no earlier than 12hrs after needle/catheter placement.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "12hrs.\r\nWe recommend that needle placement should occur at least 12hrs after a prophylactic LMWH dose.\r\nIn patients administered a dose of LMWH 2hrs preoperatively, we recommend against neuraxial techniques because needle placement would occur close to peak anti-coagulant activity.", "ap_restart_a_p": "First dose 12hrs.\r\nWe recommend the first postoperative LMWH dose should be administered at least 12hrs after needle/catheter placement. The second postoperative dose should occur no sooner than 24hrs after the first dose.\r\nIndwelling neuraxial catheters do not represent increased risk and may be maintained. However, no additional hemostasis altering medications should be administered because of the additive effects.", "ap_hold_b_c": "12hrs.", "ap_restart_a_c": "At least 4hrs.\r\nAdministration of LMWH should be delayed for 4hrs after catheter removal. We recommend the first dose of LMWH should be administered no earlier than 12hrs after needle/catheter placement."}}, {"model": "coag.coag", "pk": 12, "fields": {"drugName": "Dalteparin(therapeutic)", "nx_hold_b_p": "24hrs.\r\nDelay needle insertion at least 24hrs for treatment dose of 200U/kg or 100U/kg q12hrs.\r\nConsider checking anti-factor Xa level, particularly in elderly patients and patients with renal insufficiency. An acceptable level of residual anti-factor Xa activity to proceed with neuraxial block remains undetermined.", "nx_restart_a_p": "24-72hrs.\r\nTherapeutic-dose LMWH may be resumed 24hrs after non-high-bleeding risk surgery and 48~72hrs after high-bleeding-risk surgery.\r\nIndwelling catheters should be removed before initiation none of therapeutic LMWH treatment.", "nx_hold_b_c": "Avoid.", "nx_restart_a_c": "At least 4hrs.\r\nWe recommend that indwelling neuraxial catheters be removed 4hrs prior to the first postoperative dose and at least 24hrs after needle/catheter placement whichever is greater.", "db_hold_b_p": "24hrs.\r\nDelay needle insertion at least 24hrs for treatment dose of 200U/kg or 100U/kg q12hrs.\r\nConsider checking anti-factor Xa level, particularly in elderly patients and patients with renal insufficiency. An acceptable level of residual anti-factor Xa activity to proceed with neuraxial block remains undetermined.", "db_restart_a_p": "24-72hrs.\r\nTherapeutic-dose LMWH may be resumed 24hrs after non-high-bleeding risk surgery and 48~72hrs after high-bleeding-risk surgery.\r\nIndwelling catheters should be removed before initiation none of therapeutic LMWH treatment.", "db_hold_b_c": "Avoid.", "db_restart_a_c": "At least 4hrs.\r\nWe recommend that indwelling neuraxial catheters be removed 4hrs prior to the first postoperative dose and at least 24hrs after needle/catheter placement whichever is greater.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "24hrs.\r\nDelay needle insertion at least 24hrs for treatment dose of 200U/kg or 100U/kg q12hrs.\r\nConsider checking anti-factor Xa level, particularly in elderly patients and patients with renal insufficiency. An acceptable level of residual anti-factor Xa activity to proceed with neuraxial block remains undetermined.", "ap_restart_a_p": "24-72hrs.\r\nTherapeutic-dose LMWH may be resumed 24hrs after non-high-bleeding risk surgery and 48~72hrs after high-bleeding-risk surgery.\r\nIndwelling catheters should be removed before initiation none of therapeutic LMWH treatment.", "ap_hold_b_c": "Avoid.", "ap_restart_a_c": "At least 4hrs.\r\nWe recommend that indwelling neuraxial catheters be removed 4hrs prior to the first postoperative dose and at least 24hrs after needle/catheter placement whichever is greater."}}, {"model": "coag.coag", "pk": 13, "fields": {"drugName": "Desirudin", "nx_hold_b_p": "AVOID.\r\nNeuraxial technique not recommended.", "nx_restart_a_p": "AVOID.\r\nNeuraxial technique not recommended.", "nx_hold_b_c": "AVOID.", "nx_restart_a_c": "AVOID.\r\nNeuraxial technique not recommended.", "db_hold_b_p": "AVOID.\r\nNeuraxial technique not recommended.", "db_restart_a_p": "AVOID.\r\nNeuraxial technique not recommended.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "AVOID.\r\nNeuraxial technique not recommended.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "AVOID.\r\nNeuraxial technique not recommended.", "ap_restart_a_p": "AVOID.\r\nNeuraxial technique not recommended.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "AVOID.\r\nNeuraxial technique not recommended."}}, {"model": "coag.coag", "pk": 14, "fields": {"drugName": "Dipyridamole", "nx_hold_b_p": "24hrs.\r\nBased on the elimination half-life, we suggest discontinuing extended-release dipyridamole for 24hrs prior to neuraxial block. Aspirin may be continued perioperatively.", "nx_restart_a_p": "6hrs, AVOID with indwelling catheters.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "nx_hold_b_c": "AVOID.", "nx_restart_a_c": "6hrs, AVOID with indwelling catheters.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "db_hold_b_p": "24hrs.\r\nBased on the elimination half-life, we suggest discontinuing extended-release dipyridamole for 24hrs prior to neuraxial block. Aspirin may be continued perioperatively.", "db_restart_a_p": "6hrs, AVOID with indwelling catheters.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "6hrs, AVOID with indwelling catheters.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "24hrs.\r\nBased on the elimination half-life, we suggest discontinuing extended-release dipyridamole for 24hrs prior to neuraxial block. Aspirin may be continued perioperatively.", "ap_restart_a_p": "6hrs, AVOID with indwelling catheters.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "6hrs, AVOID with indwelling catheters.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal."}}, {"model": "coag.coag", "pk": 15, "fields": {"drugName": "Edoxaban", "nx_hold_b_p": "72hrs.\r\nWe suggest that edoxaban be discontinued 72hrs prior to neuraxial block. Consider checking edoxaban or anti-factor Xa activity level if less than 72hrs. An acceptable level of residual edoxaban activity to proceed with neuraxial block remains undetermined.", "nx_restart_a_p": "At least 6hrs, AVOID with indwelling catheters.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "nx_hold_b_c": "20-28hrs or anti-factor Xa assay", "nx_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "db_hold_b_p": "72hrs.\r\nWe suggest that edoxaban be discontinued 72hrs prior to neuraxial block. Consider checking edoxaban or anti-factor Xa activity level if less than 72hrs. An acceptable level of residual edoxaban activity to proceed with neuraxial block remains undetermined.", "db_restart_a_p": "At least 6hrs, AVOID with indwelling catheters.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "db_hold_b_c": "20-28hrs or anti-factor Xa assay.", "db_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "72hrs.\r\nWe suggest that edoxaban be discontinued 72hrs prior to neuraxial block. Consider checking edoxaban or anti-factor Xa activity level if less than 72hrs. An acceptable level of residual edoxaban activity to proceed with neuraxial block remains undetermined.", "ap_restart_a_p": "At least 6hrs, AVOID with indwelling catheters.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "ap_hold_b_c": "20-28hrs or anti-factor Xa assay.", "ap_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose."}}, {"model": "coag.coag", "pk": 16, "fields": {"drugName": "Enoxaparin(prophylaxisBID)", "nx_hold_b_p": "12hrs.\r\nWe recommend that needle placement should occur at least 12hrs after a prophylactic LMWH dose.\r\nIn patients administered a dose of LMWH 2hrs pre-operatively, we recommend against neuraxial techniques because needle placement would occur close to peak anticoagulant activity.", "nx_restart_a_p": "First dose the following day, Minimum 12hrs after needle/catheter.\r\nIndwelling catheters should be removed prior to initiation of LMWH.\r\nThis dosage regimen is associated with an increased risk of spinal hematoma. We recommend the first dose of LMWH should be administered the following day and no earlier than 12hrs after needle/catheter placement, regardless of anesthetic technique, and only in the presence of adequate hemostasis.", "nx_hold_b_c": "AVOID.", "nx_restart_a_c": "At least 4hrs.\r\nThis dosage regimen is associated with an increased risk of spinal hematoma.\r\nAdministration of LMWH should be delayed for 4hrs after catheter removal. We recommend the first dose of LMWH should be administered the following day and no earlier than 12hrs after needle/catheter placement, regardless of anesthetic technique, and only in the presence of adequate hemostasis.", "db_hold_b_p": "12hrs.\r\nWe recommend that needle placement should occur at least 12hrs after a prophylactic LMWH dose.\r\nIn patients administered a dose of LMWH 2hrs pre-operatively, we recommend against neuraxial techniques because needle placement would occur close to peak anticoagulant activity.", "db_restart_a_p": "First dose the following day, Minimum 12hrs after needle/catheter.\r\nIndwelling catheters should be removed prior to initiation of LMWH.\r\nThis dosage regimen is associated with an increased risk of spinal hematoma. We recommend the first dose of LMWH should be administered the following day and no earlier than 12hrs after needle/catheter placement, regardless of anesthetic technique, and only in the presence of adequate hemostasis.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "At least 4hrs.\r\nThis dosage regimen is associated with an increased risk of spinal hematoma.\r\nAdministration of LMWH should be delayed for 4hrs after catheter removal. We recommend the first dose of LMWH should be administered the following day and no earlier than 12hrs after needle/catheter placement, regardless of anesthetic technique, and only in the presence of adequate hemostasis.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "12hrs.\r\nWe recommend that needle placement should occur at least 12hrs after a prophylactic LMWH dose.\r\nIn patients administered a dose of LMWH 2hrs pre-operatively, we recommend against neuraxial techniques because needle placement would occur close to peak anticoagulant activity.", "ap_restart_a_p": "First dose the following day, Minimum 12hrs after needle/catheter.\r\nIndwelling catheters should be removed prior to initiation of LMWH.\r\nThis dosage regimen is associated with an increased risk of spinal hematoma. We recommend the first dose of LMWH should be administered the following day and no earlier than 12hrs after needle/catheter placement, regardless of anesthetic technique, and only in the presence of adequate hemostasis.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "At least 4hrs.\r\nThis dosage regimen is associated with an increased risk of spinal hematoma.\r\nAdministration of LMWH should be delayed for 4hrs after catheter removal. We recommend the first dose of LMWH should be administered the following day and no earlier than 12hrs after needle/catheter placement, regardless of anesthetic technique, and only in the presence of adequate hemostasis."}}, {"model": "coag.coag", "pk": 17, "fields": {"drugName": "Enoxaparin(prophylaxisQD)", "nx_hold_b_p": "12hrs.\r\nWe recommend that needle placement should occur at least 12hrs after a prophylactic LMWH dose.\r\nIn patients administered a dose of LMWH 2hrs pre-operatively, we recommend against neuraxial techniques because needle placement would occur close to peak anticoagulant activity.", "nx_restart_a_p": "First dose at least 12hrs.\r\nWe recommend the first postoperative LMWH dose should be administered at least 12hrs after needle/catheter placement. The second postoperative dose should occur no sooner than 24hrs after the first dose.\r\nIndwelling neuraxial catheters do not represent increased risk and may be maintained. However, no additional risk and may be maintained. However, no additional hemostasis altering medications should be administered because of the additive effects.", "nx_hold_b_c": "12hrs.", "nx_restart_a_c": "At least 4hrs.\r\nAdministration of LMWH should be delayed for 4hrs after catheter removal. We recommend the first dose of LMWH should be administered no earlier than 12hrs after needle/catheter placement.", "db_hold_b_p": "12hrs.\r\nWe recommend that needle placement should occur at least 12hrs after a prophylactic LMWH dose.\r\nIn patients administered a dose of LMWH 2hrs pre-operatively, we recommend against neuraxial techniques because needle placement would occur close to peak anticoagulant activity.", "db_restart_a_p": "First dose at least 12hrs.\r\nWe recommend the first postoperative LMWH dose should be administered at least 12hrs after needle/catheter placement. The second postoperative dose should occur no sooner than 24hrs after the first dose.\r\nIndwelling neuraxial catheters do not represent increased risk and may be maintained. However, no additional risk and may be maintained. However, no additional hemostasis altering medications should be administered because of the additive effects.", "db_hold_b_c": "12hrs.", "db_restart_a_c": "At least 4hrs.\r\nAdministration of LMWH should be delayed for 4hrs after catheter removal. We recommend the first dose of LMWH should be administered no earlier than 12hrs after needle/catheter placement.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "12hrs.\r\nWe recommend that needle placement should occur at least 12hrs after a prophylactic LMWH dose.\r\nIn patients administered a dose of LMWH 2hrs pre-operatively, we recommend against neuraxial techniques because needle placement would occur close to peak anticoagulant activity.", "ap_restart_a_p": "First dose at least 12hrs.\r\nWe recommend the first postoperative LMWH dose should be administered at least 12hrs after needle/catheter placement. The second postoperative dose should occur no sooner than 24hrs after the first dose.\r\nIndwelling neuraxial catheters do not represent increased risk and may be maintained. However, no additional risk and may be maintained. However, no additional hemostasis altering medications should be administered because of the additive effects.", "ap_hold_b_c": "12hrs.", "ap_restart_a_c": "At least 4hrs.\r\nAdministration of LMWH should be delayed for 4hrs after catheter removal. We recommend the first dose of LMWH should be administered no earlier than 12hrs after needle/catheter placement."}}, {"model": "coag.coag", "pk": 18, "fields": {"drugName": "Enoxaparin(therapeutic)", "nx_hold_b_p": "24hrs.\r\nDelay needle insertion at least 24hrs for treatment doses of 1mg/kg/ q12hrs or 1.5mg/kg daily.\r\nConsider checking anti-factor Xa level, particularly in elderly patients and patients with renal insufficiency. An acceptable level of residual anti-factor Xa activity to proceed with neuraxial block remains undetermined.", "nx_restart_a_p": "24-72hrs.\r\nTherapeutic dose LMWH may be resumed 24hrs after non-high-bleeding-risk surgery and 48 to 72 hrs after high-bleeding-risk surgery.\r\nIndwelling catheters should be removed before initiation none of therapeutic LMWH treatment.", "nx_hold_b_c": "AVOID.", "nx_restart_a_c": "4hrs.\r\nWe recommend that indwelling neuraxial catheters be removed 4hrs prior to the first postoperative dose and at least 24hrs after needle/catheter placement, whichever is greater.", "db_hold_b_p": "24hrs.\r\nDelay needle insertion at least 24hrs for treatment doses of 1mg/kg/ q12hrs or 1.5mg/kg daily.\r\nConsider checking anti-factor Xa level, particularly in elderly patients and patients with renal insufficiency. An acceptable level of residual anti-factor Xa activity to proceed with neuraxial block remains undetermined.", "db_restart_a_p": "24-72hrs.\r\nTherapeutic dose LMWH may be resumed 24hrs after non-high-bleeding-risk surgery and 48 to 72 hrs after high-bleeding-risk surgery.\r\nIndwelling catheters should be removed before initiation none of therapeutic LMWH treatment.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "4hrs.\r\nWe recommend that indwelling neuraxial catheters be removed 4hrs prior to the first postoperative dose and at least 24hrs after needle/catheter placement, whichever is greater.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "24hrs.\r\nDelay needle insertion at least 24hrs for treatment doses of 1mg/kg/ q12hrs or 1.5mg/kg daily.\r\nConsider checking anti-factor Xa level, particularly in elderly patients and patients with renal insufficiency. An acceptable level of residual anti-factor Xa activity to proceed with neuraxial block remains undetermined.", "ap_restart_a_p": "24-72hrs.\r\nTherapeutic dose LMWH may be resumed 24hrs after non-high-bleeding-risk surgery and 48 to 72 hrs after high-bleeding-risk surgery.\r\nIndwelling catheters should be removed before initiation none of therapeutic LMWH treatment.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "4hrs.\r\nWe recommend that indwelling neuraxial catheters be removed 4hrs prior to the first postoperative dose and at least 24hrs after needle/catheter placement, whichever is greater."}}, {"model": "coag.coag", "pk": 19, "fields": {"drugName": "Eptifibatide", "nx_hold_b_p": "AVOID until normal platelet function has recovered.\r\nWe recommend that neuraxial techniques should be avoided until platelet function as impacted by the GP IIb/IIIa inhibitor has recovered.\r\nFollowing administration, the time to normal platelet aggregation is 4 to 8 hours for eptifibatide.", "nx_restart_a_p": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitated assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued anti-thrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "nx_hold_b_c": "AVOID.", "nx_restart_a_c": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitated assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued anti-thrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "db_hold_b_p": "AVOID until normal platelet function has recovered.\r\nWe recommend that neuraxial techniques should be avoided until platelet function as impacted by the GP IIb/IIIa inhibitor has recovered.\r\nFollowing administration, the time to normal platelet aggregation is 4 to 8 hours for eptifibatide.", "db_restart_a_p": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitated assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued anti-thrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitated assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued anti-thrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "AVOID until normal platelet function has recovered.\r\nWe recommend that neuraxial techniques should be avoided until platelet function as impacted by the GP IIb/IIIa inhibitor has recovered.\r\nFollowing administration, the time to normal platelet aggregation is 4 to 8 hours for eptifibatide.", "ap_restart_a_p": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitated assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued anti-thrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitated assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued anti-thrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal."}}, {"model": "coag.coag", "pk": 20, "fields": {"drugName": "Fondaparinux", "nx_hold_b_p": "NO RECOMMENDATION.\r\nBased on the sustained and irreversible antithrombotic  effect, early postoperative dosing, and the spinal hematoma reported during initial clinical trials, we recommend that until further clinical experience is available performance of neuraxial techniques should occur under conditions used in clinical trials. If this is not feasible, an alternate method of prophylaxis should be considered.", "nx_restart_a_p": "AVOID.\r\nBased on the sustained and irreversible antithrombotic  effect, early postoperative dosing, and the spinal hematoma reported during initial clinical trials, we recommend that until further clinical experience is available performance of neuraxial techniques should occur under conditions used in clinical trials. If this is not feasible, an alternate method of prophylaxis should be considered.", "nx_hold_b_c": "AVOID.", "nx_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "db_hold_b_p": "NO RECOMMENDATION.\r\nBased on the sustained and irreversible antithrombotic  effect, early postoperative dosing, and the spinal hematoma reported during initial clinical trials, we recommend that until further clinical experience is available performance of neuraxial techniques should occur under conditions used in clinical trials. If this is not feasible, an alternate method of prophylaxis should be considered.", "db_restart_a_p": "AVOID.\r\nBased on the sustained and irreversible antithrombotic  effect, early postoperative dosing, and the spinal hematoma reported during initial clinical trials, we recommend that until further clinical experience is available performance of neuraxial techniques should occur under conditions used in clinical trials. If this is not feasible, an alternate method of prophylaxis should be considered.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "NO RECOMMENDATION.\r\nBased on the sustained and irreversible antithrombotic  effect, early postoperative dosing, and the spinal hematoma reported during initial clinical trials, we recommend that until further clinical experience is available performance of neuraxial techniques should occur under conditions used in clinical trials. If this is not feasible, an alternate method of prophylaxis should be considered.", "ap_restart_a_p": "AVOID.\r\nBased on the sustained and irreversible antithrombotic  effect, early postoperative dosing, and the spinal hematoma reported during initial clinical trials, we recommend that until further clinical experience is available performance of neuraxial techniques should occur under conditions used in clinical trials. If this is not feasible, an alternate method of prophylaxis should be considered.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose."}}, {"model": "coag.coag", "pk": 21, "fields": {"drugName": "Heparin(CPB)", "nx_hold_b_p": "Neuraxial blocks should be avoided in a patient with known coagulopathy from any cause.", "nx_restart_a_p": "60min.\r\nTime from instrumentation to systemic heparinization should exceed 60mins. Surgery should be delayed 24hrs in the event of a traumatic tap.", "nx_hold_b_c": "After normal coagulation restored.", "nx_restart_a_c": "No recommendation.", "db_hold_b_p": "Neuraxial blocks should be avoided in a patient with known coagulopathy from any cause.", "db_restart_a_p": "60min.\r\nTime from instrumentation to systemic heparinization should exceed 60mins. Surgery should be delayed 24hrs in the event of a traumatic tap.", "db_hold_b_c": "After normal coagulation restored.", "db_restart_a_c": "No recommendation", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "Neuraxial blocks should be avoided in a patient with known coagulopathy from any cause.", "ap_restart_a_p": "60min.\r\nTime from instrumentation to systemic heparinization should exceed 60mins. Surgery should be delayed 24hrs in the event of a traumatic tap.", "ap_hold_b_c": "After normal coagulation restored.", "ap_restart_a_c": "No recommendation."}}, {"model": "coag.coag", "pk": 22, "fields": {"drugName": "Heparin(IV)", "nx_hold_b_p": "4~6hrs & Normal coagulation status.\r\nDiscontinue heparin infusion 4~6hrs and verify normal coagulation status prior to neuraxial blockade. Avoid neuraxial techniques in patients with other coagulopathies.", "nx_restart_a_p": "1hr.\r\nAlthough the occurrence of a bloody or difficult neuraxial needle placement may increase risk, there are no data to support mandatory cancellation of a case. Direct communication with the surgeon and a specific risk-benefit decision about proceeding in each case are warranted.\r\nCurrently, insufficient data and experience are available to determine if the risk of neuraxial hematoma is increased when combining neuraxial techniques with the full anti-coagulation of cardiac surgery. We suggest postoperative monitoring of neurologic function and selection of neuraxial solutions that minimize sensory and motor block to facilitate detection of new/progressive neurodeficits.", "nx_hold_b_c": "4~6hrs & Normal coagulation status.", "nx_restart_a_c": "1hr.\r\nReheparinize 1hr after catheter removal.", "db_hold_b_p": "4~6hrs & Normal coagulation status.\r\nDiscontinue heparin infusion 4~6hrs and verify normal coagulation status prior to neuraxial blockade. Avoid neuraxial techniques in patients with other coagulopathies.", "db_restart_a_p": "1hr.\r\nAlthough the occurrence of a bloody or difficult neuraxial needle placement may increase risk, there are no data to support mandatory cancellation of a case. Direct communication with the surgeon and a specific risk-benefit decision about proceeding in each case are warranted.\r\nCurrently, insufficient data and experience are available to determine if the risk of neuraxial hematoma is increased when combining neuraxial techniques with the full anti-coagulation of cardiac surgery. We suggest postoperative monitoring of neurologic function and selection of neuraxial solutions that minimize sensory and motor block to facilitate detection of new/progressive neurodeficits.", "db_hold_b_c": "4~6hrs & Normal coagulation status.", "db_restart_a_c": "1hr.\r\nReheparinize 1hr after catheter removal.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "4~6hrs & Normal coagulation status.\r\nDiscontinue heparin infusion 4~6hrs and verify normal coagulation status prior to neuraxial blockade. Avoid neuraxial techniques in patients with other coagulopathies.", "ap_restart_a_p": "1hr.\r\nAlthough the occurrence of a bloody or difficult neuraxial needle placement may increase risk, there are no data to support mandatory cancellation of a case. Direct communication with the surgeon and a specific risk-benefit decision about proceeding in each case are warranted.\r\nCurrently, insufficient data and experience are available to determine if the risk of neuraxial hematoma is increased when combining neuraxial techniques with the full anti-coagulation of cardiac surgery. We suggest postoperative monitoring of neurologic function and selection of neuraxial solutions that minimize sensory and motor block to facilitate detection of new/progressive neurodeficits.", "ap_hold_b_c": "4~6hrs & Normal coagulation status.", "ap_restart_a_c": "1hr.\r\nReheparinize 1hr after catheter removal."}}, {"model": "coag.coag", "pk": 23, "fields": {"drugName": "Heparin(SCprophylaxis)", "nx_hold_b_p": "12hrs & assessment of coagulation status.\r\nPreoperative higher-dose UFH for thromboprophylaxis. We suggest neuraxial block occur 12hrs after SC heparin administration and assessment of coagulation status.", "nx_restart_a_p": "Unknown risk. Risk-Benefit assessment required.\r\nThe safety of indwelling neuraxial catheters in patients receiving doses greater than 5000U or greater than 15000U of UFH daily has not been established. We suggest that the risk and benefits be assessed on an individual basis and that techniques to facilitate detection of new/progressive neurodeficits be applied.", "nx_hold_b_c": "Unknown risk. Risk-Benefit assessment required.", "nx_restart_a_c": "Immediately.", "db_hold_b_p": "12hrs & assessment of coagulation status.\r\nPreoperative higher-dose UFH for thromboprophylaxis. We suggest neuraxial block occur 12hrs after SC heparin administration and assessment of coagulation status.", "db_restart_a_p": "Unknown risk. Risk-Benefit assessment required.\r\nThe safety of indwelling neuraxial catheters in patients receiving doses greater than 5000U or greater than 15000U of UFH daily has not been established. We suggest that the risk and benefits be assessed on an individual basis and that techniques to facilitate detection of new/progressive neurodeficits be applied.", "db_hold_b_c": "Unknown risk. Risk-Benefit assessment required.", "db_restart_a_c": "Immediately.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "12hrs & assessment of coagulation status.\r\nPreoperative higher-dose UFH for thromboprophylaxis. We suggest neuraxial block occur 12hrs after SC heparin administration and assessment of coagulation status.", "ap_restart_a_p": "Unknown risk. Risk-Benefit assessment required.\r\nThe safety of indwelling neuraxial catheters in patients receiving doses greater than 5000U or greater than 15000U of UFH daily has not been established. We suggest that the risk and benefits be assessed on an individual basis and that techniques to facilitate detection of new/progressive neurodeficits be applied.", "ap_hold_b_c": "Unknown risk. Risk-Benefit assessment required.", "ap_restart_a_c": "Immediately."}}, {"model": "board.board", "pk": 1, "fields": {"title": "test", "contents": "test", "author": "test", "created_date": "2024-06-25T05:34:00Z", "modified_date": "2024-06-25T05:34:00Z"}}, {"model": "exam.exam", "pk": 1, "fields": {"title": "test", "description": "test", "date_created": "2024-07-02T14:05:01.460Z"}}, {"model": "exam.exam", "pk": 2, "fields": {"title": "2023 ITE", "description": "2023 년 대한마취통증의학회\r\n전공의 수련평가시험 (In Training Exam, ITE) 문제", "date_created": "2024-07-04T04:52:00.801Z"}}, {"model": "exam.question", "pk": 1, "fields": {"exam": 1, "question_text": "this is test question1", "image": "question_images/20230929_155209.jpg", "option1": "a1", "option2": "a2", "option3": "a3", "option4": "a4", "option5": "a5", "correct_option": "a5", "comment": "default", "comment_image": ""}}, {"model": "exam.question", "pk": 2, "fields": {"exam": 1, "question_text": "this is test question2", "image": "", "option1": "aa11", "option2": "aa22", "option3": "aa33", "option4": "aa44", "option5": "aa55", "correct_option": "aa11", "comment": "default", "comment_image": ""}}, {"model": "exam.question", "pk": 3, "fields": {"exam": 2, "question_text": "문1. 일측폐환기를 이용한 폐절제술에서 적절한 수액관리 전략으로 옳은 것은?", "image": "", "option1": "소변량은 시간당 2 ml/kg 이상이 되도록 조절한다", "option2": "평균 성인에서 첫 24 시간동안 crystalloid 는 최소 3 L 이상 보충하여야 한다.", "option3": "수술 첫 24 시간 수액균형(fluid balance)은 50 ml/kg 를 초과하지 않도록 조절한다.", "option4": "Third-space loss 를 고려하여 수액량을 증량한다", "option5": "수술 후 조직관류를 개선하기 위해 수액주입보다 inotrope 사용이 더 선호된다", "correct_option": "5", "comment": "㉮ Urine output greater than 0.5 ml/kg/h is unnecessary.\r\n㉯ For an average adult patient, crystalloid administration should be limited to less than 3 L in \r\nthe first 24 h.\r\n㉰ Total positive fluid balance in the first 24-h perioperative period should not exceed 20 \r\nmL/kg.\r\n㉱ No fluid administration for third-space fluid losses during pulmonary resection.\r\n㉲ If increased tissue perfusion is needed postoperatively, it is preferable to use invasive \r\nmonitoring and inotropes rather than to cause fluid overload.\r\n참고문헌: Miller RD: Miller’s Anesthesia. 9th ed. pp 1676. BOX 53.11", "comment_image": ""}}, {"model": "exam.question", "pk": 4, "fields": {"exam": 2, "question_text": "문 2. 68 세 남자환자가 우측폐 중엽에 발견된 폐암을 절제하기 위해 일측폐환기를 적용한 전신마취를\r\n시행할 예정이다. 환자는 3 년전 만성폐쇄폐질환을 진단받았으며, 간헐적으로 필요 시마다\r\n기관지확장제 흡입 치료를 시행하고 있고, 5 년전 진단받은 고혈압, 당뇨로 식이요법과 혈압약을\r\n복용 중이다. 이 환자의 수술전 평가와 마취 관리에 대한 내용 중 적절한 것은?", "image": "", "option1": "㉮ 폐기능 검사상 정상 범위의 FEV1 혹은 FVC 가 관찰된다면 일측폐환기 중 저산소증 발생 가능성은 현저하게 감소한다.", "option2": "㉯ 수술전 항암 화학요법을 시행한 환자는 통증조절 계획에 일차적으로 opioids 보다 NSAIDs 를 포함하는 것이 유리하다.", "option3": "㉰ 우측폐를 폐쇄하는 일측폐환기는 좌측폐를 폐쇄하는 것보다 저산소증 가능성이 낮다.", "option4": "㉱ 폐동맥 고혈압이 동반된 경우 수술 중 vasopressin 사용은 폐동맥압력을 증가시키므로 금기이다.", "option5": "㉲ 폐의 우중엽은 기능적 폐용적이 가장 작은 폐엽으로 predicted postoperative FEV1%상 수술 후 폐기능 유지에 유리하다.", "correct_option": "㉲", "comment": "㉮ 일측폐 환기를 받는 환자가 만성폐질환을 동반할 때, 폐쇄의 정도가 심할수록 일측폐 환기 중\r\n저산소증을 보일 가능성은 낮다. \r\n㉯ 수술 전 화학요법으로 cisplatin 을 투여 받은 경우 NSAIDs 사용은 신장기능의 악화를 유발할\r\n가능성이 높다. \r\n㉰ 우측폐의 용적이 좌측폐보다 약 10%가량 크기 때문에 우측폐를 폐쇄하는 경우 shunt 발생양이\r\n증가하여 저산소증이 잘 발생한다. \r\n㉱ Vasopressin 은 폐동맥 고혈압 환자에서 폐동맥압 상승 없이 전신동맥 혈압을 효과적으로\r\n상승시킨다. \r\n㉲ 폐의 우중엽은 기능적 폐용적이 4 로 가장 작은 폐엽이다.", "comment_image": ""}}, {"model": "exam.question", "pk": 5, "fields": {"exam": 2, "question_text": "문 5. 47 세 남자가 응급개복술을 받기 위해 수술실에 입실하였다. 전신마취 유도를 위해 propofol 2.0 \r\nmg/kg 과 rocuronium 1.0 mg/kg 을 투여하였고, 신경근차단 감시 상 사연속자극(TOF)이 0 을 확인하였다. \r\n마스크 환기 후 직접후두경을 이용하여 기관내삽관을 3 회 시도했으나 모두 실패하였다. 이 후 마스크\r\n환기가 적절히 되지 않아 도움을 요청한 후 다음 중 가장 먼저 시도해 볼 수 있는 적절한 대처 방법은?", "image": "", "option1": "㉮ Propofol 과 rocuronium 추가 투여", "option2": "㉯ 반지갑상연골절개(cricothyrotomy)", "option3": "㉰ 성문위기도유지기(supraglottic airway) 삽입", "option4": "㉱ Dexamethasone 5 mg 투여", "option5": "㉲ 이비인후과에 기관절개술(tracheostomy) 요청", "correct_option": "㉰", "comment": "해설: 2022 ASA difficult airway algorithm 참조\r\n참고문헌: 마취통증의학 4 판, 여문각, pp376-7, Miller’s anesthesia, 9th edition, pp 1375", "comment_image": ""}}, {"model": "exam.question", "pk": 6, "fields": {"exam": 2, "question_text": "문 6. 나이가 증가함에 따라 심혈관계의 생리적 및 병리적인 변화에 대한 설명으로 가장 옳은 것은?", "image": "", "option1": "㉮ 정맥 혈전 색전증이 감소한다.", "option2": "㉯ 심장의 이완기 기능은 비교적 잘 유지된다.", "option3": "㉰ 후부하는 감소한다.", "option4": "㉱ 심근 산소 소비량은 감소한다.", "option5": "㉲ 혈관 순응도는 감소한다.", "correct_option": "㉲", "comment": "㉮ 정맥 혈전 색전증(venous thromboembolism)이 증가한다.\r\n㉯ 심장의 이완기 기능 이상(diastolic dysfunction)이 흔하다.\r\n㉰ 후부하(afterload)는 증가한다.\r\n㉱ 심근 산소 소비량(myocardial oxygen consumption)은 증가한다.\r\n참고문헌: Michael A. Gropper: Miller’s Anesthesia. 9th ed. Pp 2103-2104", "comment_image": ""}}, {"model": "exam.question", "pk": 7, "fields": {"exam": 2, "question_text": "문 7. 나이가 증가함에 따라 자율신경계의 생리적 및 병리적인 변화에 대한 설명으로 가장 옳은 것은?", "image": "", "option1": "㉮ β-아드레날린 민감도는 잘 유지된다.", "option2": "㉯ 최대 심박수는 감소한다.", "option3": "㉰ β-작용제에 대한 반응은 증가한다.", "option4": "㉱ 심박출량은 증가한다.", "option5": "㉲ 기립성 저혈압은 감소한다.", "correct_option": "㉯", "comment": "㉮ β-아드레날린 민감도(β-adrenergic sensitivity)는 감소한다.\r\n㉰ β-작용제에 대한 반응(responsiveness to β-agonists)은 감소한다.\r\n㉱ 심박출량(cardiac output)은 감소한다.\r\n㉲ 기립성 저혈압(orthostatic hypotension)은 증가한다.\r\n \r\n참고문헌: Michael A. Gropper: Miller’s Anesthesia. 9th ed. Pp 2105", "comment_image": ""}}, {"model": "exam.question", "pk": 8, "fields": {"exam": 2, "question_text": "문 8. 88 세 환자가 신장암을 진단받아 로봇 신장절제술을 시행받았다. 환자는 중증도의 치매를 앓고\r\n있었고, 청력저하로 의사소통이 어려웠다. 또한 중증도 이상의 목동맥 협착을 진단받아\r\n클로피도그렐을 복용하고 있었고, 수술 5 일전 복용을 중단하였다. 데스플루란과 레미펜타닐을\r\n이용한 전신마취 하에 수술을 시행하였고, 수술 종료 후 마취에서 회복하는 과정에서 떨림현상이\r\n관찰되어 메페리딘을 투여하였다. 회복실에서 환자가 지속적으로 소리를 지르며 침대에서\r\n일어나려고 하고, 거치되어 있는 수액 라인을 제거하려는 행동이 관찰되었다. 다음 중 이 환자에서\r\n관찰되는 현상의 위험인자가 아닌 것은?", "image": "", "option1": "㉮ 88 세", "option2": "㉯ 중증도의 치매", "option3": "㉰ 의사소통이 어려울 정도의 청력저하", "option4": "㉱ 5 일전 복용 중단한 클로피도그렐", "option5": "㉲ 메페리딘", "correct_option": "㉱", "comment": "Major predisposing patient risk factors include (1) age greater than 65 years, (2) cognitive \r\nimpairment, (3) severe illness or comorbidity burden, (4) hearing or vision impairment, and (5) \r\npresence of infection… (중략) Once in the recovery room, any deliriogenic medications should be \r\navoided (e.g., anticholinergics, sedative-hypnotics, meperidine), unless…\r\n참고문헌: Miller RD: Miller’s Anesthesia. 9th ed. pp 2604", "comment_image": ""}}, {"model": "exam.question", "pk": 9, "fields": {"exam": 2, "question_text": "문 9. 경추 손상이 의심되는 두부손상 환자의 응급수술을 위한 기관내삽관 시 적합한 position 및\r\n약제에 대한 설명으로 옳은 것은?", "image": "", "option1": "㉮ Sniff position 을 취한다.", "option2": "㉯ 후두부를 바닥에 고정한 상태로 시행한다.", "option3": "㉰ Atlanto-occipital extension 을 제한하지 않는다.", "option4": "㉱ Ramped position 을 취한다.", "option5": "㉲ Succinylcholine 은 금기이다.", "correct_option": "㉯", "comment": "두부손상 환자에서 경추 손상이 동반되는 경우 후두부를 바닥에 단단히 고정시킨 상태에서\r\nin-line stabilization 을 유지한다.\r\nSuccinylcholine: 머릿속압력 상승의 위험성 때문에 succinylcholine 사용에 있어서 이견이 있기는\r\n하지만, 기도유지 및 적절한 환기가 더욱 중요하다고 판단했다면 succinylcholine 을 주저하지\r\n않는다. 또한, 위 충만으로 인해 신속기도삽관이 필요한 경우에도 succinylcholine 이 유용하다.\r\n참고문헌: Miller’s Anesthesia. 9th ed. pp 1892.\r\n대한뇌신경마취학회: 뇌신경마취학 pp 160-1", "comment_image": ""}}, {"model": "exam.question", "pk": 10, "fields": {"exam": 2, "question_text": "문 10. 35 세 여자가 두통과 시야장애를 증상으로 내원하여 시행한 자기공명영상 결과 16 \r\nmm 크기의 뇌하수체 선종이 발견되어 경접형동접근법으로 수술을 진행하기로 하였다. 수술\r\n후 신경학적 합병증을 줄이기 위해 수술 중 시각유발전위(visual evoked potential, VEP)를\r\n시행하기로 하였다. 다음 중 VEP 에 미치는 영향이 가장 적은 약물은?", "image": "", "option1": "㉮ Sevoflurane", "option2": "㉯ Desflurane", "option3": "㉰ Etomidate", "option4": "㉱ Propofol", "option5": "㉲ Rocuronium", "correct_option": "㉲", "comment": ": VEP 는 눈에 가해진 광자극이 시신경을 통하여 시각겉질인 후두엽으로 전달된다. VEP 는\r\n마취제에 매우 민감하나 신경근차단제가 미치는 영향은 미미하다.\r\n참고문헌: 뇌신경마취학, 1st edition p118-133", "comment_image": ""}}, {"model": "exam.question", "pk": 11, "fields": {"exam": 2, "question_text": "문 11. 46 세 여자 뇌하수체 선종 환자가 갑작스러운 뇌하수체졸증(pituitary apoplexy)으로\r\n아무 전처치 없이 수술장에 입실하였다. 다음 중 우선적으로 투여를 고려해야 할 약제 또는\r\n호르몬은?", "image": "", "option1": "㉮ Aldosterone", "option2": "㉯ Hydrocortisone", "option3": "㉰ Growth hormone", "option4": "㉱ Sex hormone", "option5": "㉲ Antidiuretic hormone", "correct_option": "㉯", "comment": "Glucocorticoid 는 혈압과 혈관긴장도를 조절한다. Glucocorticoid 의 혈관긴장도에 관여하는\r\n작용은 prostacyclin (PGI2)을 억제하는 작용으로 설명된다. 체내 glucocorticoid 가 부족할\r\n경우 PGI2 의 농도가 증가하여 혈관긴장도가 감소하여 혈관확장이 일어나고 저혈압이\r\n발생한다. 그러므로 수술 전 glucocorticoid 가 부족한 환자에게는 마취전과 수술 중, \r\n수술 후에 cortisol 의 투여를 고려하여야 한다.\r\n참고문헌: 대한뇌신경마취학회: 뇌신경마취학 pp275", "comment_image": ""}}, {"model": "exam.question", "pk": 12, "fields": {"exam": 2, "question_text": "문 12. 과거력상 고혈압이 있는 57 세 여자가 건강검진에서 뇌동맥류가 발견되어 코일\r\n색전술(coil embolization)을 받기 위해 내원하였다. 환자는 당일 혈압약을 복용하지\r\n못하였으나 수술 전 혈압은 130/70 mmHg 으로 잘 조절되고 있었다. 전신마취의 유도 및\r\n유지 중 특이사항은 없었다. 카테터는 특이사항 없이 정상적으로 진입이 되었으나, 코일이\r\n삽입되던 중 갑작스럽게 혈압이 180/130 mmHg 으로 증가하였다. 혈압 상승과 함께\r\n심전도에서 서맥과 T-wave inversion 이 나타났으며 bispectral index (BIS) 수치가 54 에서\r\n10 으로 급감하였다. 가장 의심이 되는 진단명은 무엇인가?", "image": "", "option1": "㉮ 혈압약 미복용으로 인한 혈압 상승", "option2": "㉯ 카테터로 인한 뇌의 허혈성 손상", "option3": "㉰ 시술 중 통증으로 인한 환자 반응", "option4": "㉱ 뇌동맥류 파열로 인한 지주막하 출혈", "option5": "㉲ 얕은 마취심도로 인한 환자 변화", "correct_option": "㉱", "comment": "뇌동맥류 파열 시 발생하는 지주막하 출혈의 경우 혈압상승과 심전도상 변화가 나타난다.\r\n코일이 삽입되기 전까지는 증상이 없었기 때문에 카테터로 인한 허혈성 변화 가능성은\r\n적다.\r\n참고문헌: 뇌신경마취학. 제 4 장 두개내 혈관질환 수술의 마취관리. pp 223-7", "comment_image": ""}}, {"model": "exam.question", "pk": 13, "fields": {"exam": 2, "question_text": "문 13. 55 세 남자 환자가 두통을 증상으로 내원하여 시행한 자기공명영상 결과 두개저(skull \r\nbase) 뇌종양이 발견되어 개두술하 종양제거술 시행하기로 하였다. 이 환자에게 수액요법을\r\n시행할 때 장시간 과량 투여할 경우 과염소성 대사성산증(hyperchloremic metabolic \r\nacidosis)을 유발할 수 있어 주의가 필요한 수액은?", "image": "", "option1": "㉮ Normal saline", "option2": "㉯ Half-saline", "option3": "㉰ Lactate Ringer solution", "option4": "㉱ 5% dextrose solution", "option5": "㉲ PlasmaLyte", "correct_option": "㉮", "comment": ": 뇌신경마취에서 흔히 사용하는 생리식염수는 과량을 투여할 경우 희석효과로 인해\r\n과염소성 대사성산증이 유발될 수 있으므로 주의해야 한다.\r\n참고문헌: 뇌신경마취학, 1st edition p150", "comment_image": ""}}, {"model": "exam.question", "pk": 14, "fields": {"exam": 2, "question_text": "문 14. 49 세 남자 환자가 교통사고로 인한 외상성 경막외 출혈로 전신마취하에 개두술을\r\n시행 예정이다. 모든 환자 감시장치 소견은 정상이었으며 수술실 입실 후 측정한\r\n맥박산소포화도는 98%로 측정되었다. 흡입산소농도 50%에서 시행한 동맥혈 검사는 pH \r\n7.402, PaCO2 42 mmHg, PaO2 160 mmHg, BE -1.01 mmol/L 였다. 수술 전 시행한 폐\r\n초음파는 다음과 같다. 소견으로 가장 적절한 것은?", "image": "question_images/2023_14.jpeg", "option1": "㉮ 정상", "option2": "㉯ 흉수", "option3": "㉰ 폐부종", "option4": "㉱ 흡인성 폐렴", "option5": "㉲ 폐공기색전증", "correct_option": "㉮", "comment": "Below the pleura, hyperechoic horizontal reverberation artifacts at regular distances are referred \r\nto as A lines (see Fig. 41.27A).\r\nIn normal aerated lung, hyperechoic, horizontal lines arising at regular intervals from the pleural \r\nline can be seen, which are called A-lines. These are reverberation artifacts that arise when the \r\nultrasound beam reflects off of the pleura and, instead of entering the probe, partially reflects off \r\nof the probe face back to the pleura again before getting back to the machine.\r\nA-line 만 관찰되는 정상 폐초음파 소견이다. \r\n참고문헌 Miller's Anesthesia 9 판 pp 1328-1329", "comment_image": ""}}, {"model": "admin.logentry", "pk": 1, "fields": {"action_time": "2024-06-24T06:43:18.666Z", "user": 1, "content_type": 1, "object_id": "1", "object_repr": "Coag object (1)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 2, "fields": {"action_time": "2024-06-24T08:01:27.439Z", "user": 1, "content_type": 1, "object_id": "1", "object_repr": "Coag object (1)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 3, "fields": {"action_time": "2024-06-24T08:07:07.700Z", "user": 1, "content_type": 1, "object_id": "2", "object_repr": "Coag object (2)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 4, "fields": {"action_time": "2024-06-24T08:09:05.497Z", "user": 1, "content_type": 1, "object_id": "3", "object_repr": "Coag object (3)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 5, "fields": {"action_time": "2024-06-24T08:13:01.201Z", "user": 1, "content_type": 1, "object_id": "4", "object_repr": "Coag object (4)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 6, "fields": {"action_time": "2024-06-24T08:21:10.645Z", "user": 1, "content_type": 1, "object_id": "5", "object_repr": "Coag object (5)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 7, "fields": {"action_time": "2024-06-24T08:23:07.008Z", "user": 1, "content_type": 1, "object_id": "6", "object_repr": "Coag object (6)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 8, "fields": {"action_time": "2024-06-25T05:34:05.305Z", "user": 1, "content_type": 9, "object_id": "1", "object_repr": "Board object (1)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 9, "fields": {"action_time": "2024-06-26T05:51:56.365Z", "user": 1, "content_type": 6, "object_id": "2", "object_repr": "tests", "action_flag": 3, "change_message": ""}}, {"model": "admin.logentry", "pk": 10, "fields": {"action_time": "2024-06-26T09:20:50.830Z", "user": 1, "content_type": 1, "object_id": "7", "object_repr": "Coag object (7)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 11, "fields": {"action_time": "2024-06-28T05:54:22.153Z", "user": 1, "content_type": 1, "object_id": "8", "object_repr": "Coag object (8)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 12, "fields": {"action_time": "2024-06-28T06:00:10.597Z", "user": 1, "content_type": 1, "object_id": "9", "object_repr": "Coag object (9)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 13, "fields": {"action_time": "2024-06-28T06:07:20.544Z", "user": 1, "content_type": 1, "object_id": "10", "object_repr": "Coag object (10)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 14, "fields": {"action_time": "2024-06-28T06:14:43.839Z", "user": 1, "content_type": 1, "object_id": "11", "object_repr": "Coag object (11)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 15, "fields": {"action_time": "2024-06-28T06:20:17.624Z", "user": 1, "content_type": 1, "object_id": "12", "object_repr": "Coag object (12)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 16, "fields": {"action_time": "2024-06-28T06:22:17.454Z", "user": 1, "content_type": 1, "object_id": "13", "object_repr": "Coag object (13)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 17, "fields": {"action_time": "2024-07-02T14:05:01.462Z", "user": 1, "content_type": 10, "object_id": "1", "object_repr": "test", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 18, "fields": {"action_time": "2024-07-02T14:15:21.841Z", "user": 1, "content_type": 11, "object_id": "1", "object_repr": "testing", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 19, "fields": {"action_time": "2024-07-02T14:15:41.827Z", "user": 1, "content_type": 11, "object_id": "1", "object_repr": "q1", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Question text\"]}}]"}}, {"model": "admin.logentry", "pk": 20, "fields": {"action_time": "2024-07-02T15:14:23.161Z", "user": 1, "content_type": 11, "object_id": "1", "object_repr": "q1", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Option1\", \"Option2\", \"Option3\", \"Option4\", \"Correct option\"]}}]"}}, {"model": "admin.logentry", "pk": 21, "fields": {"action_time": "2024-07-02T15:18:57.232Z", "user": 1, "content_type": 11, "object_id": "1", "object_repr": "q1", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 22, "fields": {"action_time": "2024-07-02T15:29:53.401Z", "user": 1, "content_type": 11, "object_id": "1", "object_repr": "q1", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Option5\"]}}]"}}, {"model": "admin.logentry", "pk": 23, "fields": {"action_time": "2024-07-02T15:30:02.518Z", "user": 1, "content_type": 11, "object_id": "1", "object_repr": "this is test question1", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Question text\"]}}]"}}, {"model": "admin.logentry", "pk": 24, "fields": {"action_time": "2024-07-02T15:30:22.050Z", "user": 1, "content_type": 11, "object_id": "2", "object_repr": "this is test question2", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 25, "fields": {"action_time": "2024-07-02T15:30:29.578Z", "user": 1, "content_type": 11, "object_id": "1", "object_repr": "this is test question1", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 26, "fields": {"action_time": "2024-07-02T16:02:51.393Z", "user": 1, "content_type": 11, "object_id": "1", "object_repr": "this is test question1", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Image\"]}}]"}}, {"model": "admin.logentry", "pk": 27, "fields": {"action_time": "2024-07-03T03:56:42.426Z", "user": 1, "content_type": 1, "object_id": "14", "object_repr": "Coag object (14)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 28, "fields": {"action_time": "2024-07-04T04:52:00.807Z", "user": 1, "content_type": 10, "object_id": "2", "object_repr": "2023 ITE", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 29, "fields": {"action_time": "2024-07-04T04:53:43.312Z", "user": 1, "content_type": 11, "object_id": "3", "object_repr": "일측폐환기를 이용한 폐절제술에서 적절한 수액관리 전략으로 옳은 것은?", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 30, "fields": {"action_time": "2024-07-04T04:54:27.955Z", "user": 1, "content_type": 11, "object_id": "3", "object_repr": "문1. 일측폐환기를 이용한 폐절제술에서 적절한 수액관리 전략으로 옳은 것은?", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Question text\"]}}]"}}, {"model": "admin.logentry", "pk": 31, "fields": {"action_time": "2024-07-04T05:22:23.153Z", "user": 1, "content_type": 11, "object_id": "3", "object_repr": "문1. 일측폐환기를 이용한 폐절제술에서 적절한 수액관리 전략으로 옳은 것은?", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Comment\"]}}]"}}, {"model": "admin.logentry", "pk": 32, "fields": {"action_time": "2024-07-04T05:25:45.712Z", "user": 1, "content_type": 11, "object_id": "4", "object_repr": "문 2. 68 세 남자환자가 우측폐 중엽에 발견된 폐암을 절제하기 위해 일측폐환기를 적용한 전신마취를\r\n시행할 예정이다. 환자는 3 년전 만성폐쇄폐질환을 진단받았으며, 간헐적으로 필요 시마다\r\n기관지확장제 흡입 치료를 시행하고 있고, 5 년전 진단받은 고혈압, 당뇨로 식이요법과 혈압약을\r\n복용 중이다. 이 환자의 수술전 평가와 마취 관리에 대한 내용 중 적", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 33, "fields": {"action_time": "2024-07-04T05:44:23.350Z", "user": 1, "content_type": 11, "object_id": "5", "object_repr": "문 5. 47 세 남자가 응급개복술을 받기 위해 수술실에 입실하였다. 전신마취 유도를 위해 propofol 2.0 \r\nmg/kg 과 rocuronium 1.0 mg/kg 을 투여하였고, 신경근차단 감시 상 사연속자극(TOF)이 0 을 확인하였다. \r\n마스크 환기 후 직접후두경을 이용하여 기관내삽관을 3 회 시도했으나 모두 실패하였다. 이 후 마스크\r\n환기가", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 34, "fields": {"action_time": "2024-07-04T05:45:06.807Z", "user": 1, "content_type": 11, "object_id": "6", "object_repr": "문 6. 나이가 증가함에 따라 심혈관계의 생리적 및 병리적인 변화에 대한 설명으로 가장 옳은 것은?", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 35, "fields": {"action_time": "2024-07-04T05:48:44.547Z", "user": 1, "content_type": 11, "object_id": "7", "object_repr": "문 7. 나이가 증가함에 따라 자율신경계의 생리적 및 병리적인 변화에 대한 설명으로 가장 옳은 것은?", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 36, "fields": {"action_time": "2024-07-04T05:49:46.457Z", "user": 1, "content_type": 11, "object_id": "8", "object_repr": "문 8. 88 세 환자가 신장암을 진단받아 로봇 신장절제술을 시행받았다. 환자는 중증도의 치매를 앓고\r\n있었고, 청력저하로 의사소통이 어려웠다. 또한 중증도 이상의 목동맥 협착을 진단받아\r\n클로피도그렐을 복용하고 있었고, 수술 5 일전 복용을 중단하였다. 데스플루란과 레미펜타닐을\r\n이용한 전신마취 하에 수술을 시행하였고, 수술 종료 후 마취에서 회복하는 과", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 37, "fields": {"action_time": "2024-07-04T05:51:15.995Z", "user": 1, "content_type": 11, "object_id": "9", "object_repr": "문 9. 경추 손상이 의심되는 두부손상 환자의 응급수술을 위한 기관내삽관 시 적합한 position 및\r\n약제에 대한 설명으로 옳은 것은?", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 38, "fields": {"action_time": "2024-07-04T05:51:55.367Z", "user": 1, "content_type": 11, "object_id": "10", "object_repr": "문 10. 35 세 여자가 두통과 시야장애를 증상으로 내원하여 시행한 자기공명영상 결과 16 \r\nmm 크기의 뇌하수체 선종이 발견되어 경접형동접근법으로 수술을 진행하기로 하였다. 수술\r\n후 신경학적 합병증을 줄이기 위해 수술 중 시각유발전위(visual evoked potential, VEP)를\r\n시행하기로 하였다. 다음 중 VEP 에 미치는 영향이 가장 ", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 39, "fields": {"action_time": "2024-07-04T05:52:48.537Z", "user": 1, "content_type": 11, "object_id": "11", "object_repr": "문 11. 46 세 여자 뇌하수체 선종 환자가 갑작스러운 뇌하수체졸증(pituitary apoplexy)으로\r\n아무 전처치 없이 수술장에 입실하였다. 다음 중 우선적으로 투여를 고려해야 할 약제 또는\r\n호르몬은?", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 40, "fields": {"action_time": "2024-07-04T05:53:44.864Z", "user": 1, "content_type": 11, "object_id": "12", "object_repr": "문 12. 과거력상 고혈압이 있는 57 세 여자가 건강검진에서 뇌동맥류가 발견되어 코일\r\n색전술(coil embolization)을 받기 위해 내원하였다. 환자는 당일 혈압약을 복용하지\r\n못하였으나 수술 전 혈압은 130/70 mmHg 으로 잘 조절되고 있었다. 전신마취의 유도 및\r\n유지 중 특이사항은 없었다. 카테터는 특이사항 없이 정상적으로 진입이 되었", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 41, "fields": {"action_time": "2024-07-04T05:54:25.733Z", "user": 1, "content_type": 11, "object_id": "13", "object_repr": "문 13. 55 세 남자 환자가 두통을 증상으로 내원하여 시행한 자기공명영상 결과 두개저(skull \r\nbase) 뇌종양이 발견되어 개두술하 종양제거술 시행하기로 하였다. 이 환자에게 수액요법을\r\n시행할 때 장시간 과량 투여할 경우 과염소성 대사성산증(hyperchloremic metabolic \r\nacidosis)을 유발할 수 있어 주의가 필요한 수액은?", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 42, "fields": {"action_time": "2024-07-04T05:55:23.154Z", "user": 1, "content_type": 11, "object_id": "14", "object_repr": "문 14. 49 세 남자 환자가 교통사고로 인한 외상성 경막외 출혈로 전신마취하에 개두술을\r\n시행 예정이다. 모든 환자 감시장치 소견은 정상이었으며 수술실 입실 후 측정한\r\n맥박산소포화도는 98%로 측정되었다. 흡입산소농도 50%에서 시행한 동맥혈 검사는 pH \r\n7.402, PaCO2 42 mmHg, PaO2 160 mmHg, BE -1.01 mmol/L", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 43, "fields": {"action_time": "2024-07-04T06:44:01.476Z", "user": 1, "content_type": 1, "object_id": "15", "object_repr": "Coag object (15)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 44, "fields": {"action_time": "2024-07-04T07:14:23.040Z", "user": 1, "content_type": 1, "object_id": "16", "object_repr": "Coag object (16)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 45, "fields": {"action_time": "2024-07-04T07:14:38.221Z", "user": 1, "content_type": 1, "object_id": "16", "object_repr": "Coag object (16)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 46, "fields": {"action_time": "2024-07-04T07:15:17.211Z", "user": 1, "content_type": 1, "object_id": "17", "object_repr": "Coag object (17)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 47, "fields": {"action_time": "2024-07-04T07:20:07.815Z", "user": 1, "content_type": 1, "object_id": "17", "object_repr": "Coag object (17)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx hold b p\", \"Nx restart a p\", \"Nx hold b c\", \"Nx restart a c\", \"Db hold b p\", \"Db restart a p\", \"Db hold b c\", \"Db restart a c\", \"Sp hold b p\", \"Sp restart a p\", \"Sp hold b c\", \"Sp restart a c\", \"Ap hold b p\", \"Ap restart a p\", \"Ap hold b c\", \"Ap restart a c\"]}}]"}}, {"model": "admin.logentry", "pk": 48, "fields": {"action_time": "2024-07-04T07:25:49.565Z", "user": 1, "content_type": 1, "object_id": "18", "object_repr": "Coag object (18)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 49, "fields": {"action_time": "2024-07-04T07:32:00.882Z", "user": 1, "content_type": 1, "object_id": "19", "object_repr": "Coag object (19)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 50, "fields": {"action_time": "2024-07-08T04:54:11.266Z", "user": 1, "content_type": 1, "object_id": "20", "object_repr": "Coag object (20)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 51, "fields": {"action_time": "2024-07-08T05:02:08.811Z", "user": 1, "content_type": 1, "object_id": "21", "object_repr": "Coag object (21)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 52, "fields": {"action_time": "2024-07-08T05:02:35.687Z", "user": 1, "content_type": 1, "object_id": "22", "object_repr": "Coag object (22)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 53, "fields": {"action_time": "2024-07-08T05:14:29.393Z", "user": 1, "content_type": 1, "object_id": "22", "object_repr": "Coag object (22)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx hold b p\", \"Nx restart a p\", \"Nx hold b c\", \"Nx restart a c\", \"Db hold b p\", \"Db restart a p\", \"Db hold b c\", \"Db restart a c\", \"Sp hold b p\", \"Sp restart a p\", \"Sp hold b c\", \"Sp restart a c\", \"Ap hold b p\", \"Ap restart a p\", \"Ap hold b c\", \"Ap restart a c\"]}}]"}}, {"model": "admin.logentry", "pk": 54, "fields": {"action_time": "2024-07-08T05:28:42.781Z", "user": 1, "content_type": 1, "object_id": "23", "object_repr": "Coag object (23)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 55, "fields": {"action_time": "2024-07-08T13:12:39.263Z", "user": 1, "content_type": 1, "object_id": "20", "object_repr": "Coag object (20)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx hold b p\", \"Nx restart a p\", \"Nx hold b c\", \"Nx restart a c\", \"Db hold b p\", \"Db restart a p\", \"Db hold b c\", \"Db restart a c\", \"Ap hold b p\", \"Ap restart a p\", \"Ap hold b c\", \"Ap restart a c\"]}}]"}}, {"model": "admin.logentry", "pk": 56, "fields": {"action_time": "2024-07-08T13:12:45.878Z", "user": 1, "content_type": 1, "object_id": "23", "object_repr": "Coag object (23)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 57, "fields": {"action_time": "2024-07-08T13:12:55.041Z", "user": 1, "content_type": 1, "object_id": "22", "object_repr": "Coag object (22)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 58, "fields": {"action_time": "2024-07-08T13:13:08.809Z", "user": 1, "content_type": 1, "object_id": "21", "object_repr": "Coag object (21)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx restart a p\", \"Nx restart a c\", \"Db restart a p\", \"Ap restart a p\", \"Ap restart a c\"]}}]"}}, {"model": "admin.logentry", "pk": 59, "fields": {"action_time": "2024-07-08T13:14:38.387Z", "user": 1, "content_type": 1, "object_id": "1", "object_repr": "Coag object (1)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx restart a p\", \"Nx hold b c\", \"Nx restart a c\", \"Db restart a p\", \"Db hold b c\", \"Db restart a c\", \"Ap restart a p\", \"Ap hold b c\", \"Ap restart a c\"]}}]"}}, {"model": "admin.logentry", "pk": 60, "fields": {"action_time": "2024-07-08T13:14:57.448Z", "user": 1, "content_type": 1, "object_id": "2", "object_repr": "Coag object (2)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx restart a p\", \"Nx restart a c\", \"Db restart a p\", \"Db hold b c\", \"Db restart a c\", \"Ap restart a p\", \"Ap hold b c\", \"Ap restart a c\"]}}]"}}, {"model": "admin.logentry", "pk": 61, "fields": {"action_time": "2024-07-08T13:15:13.684Z", "user": 1, "content_type": 1, "object_id": "3", "object_repr": "Coag object (3)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx hold b p\", \"Nx restart a p\", \"Nx hold b c\", \"Nx restart a c\", \"Db hold b p\", \"Db restart a p\", \"Db hold b c\", \"Db restart a c\", \"Ap hold b p\", \"Ap restart a p\", \"Ap hold b c\", \"Ap restart a c\"]}}]"}}, {"model": "admin.logentry", "pk": 62, "fields": {"action_time": "2024-07-08T13:15:22.607Z", "user": 1, "content_type": 1, "object_id": "4", "object_repr": "Coag object (4)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 63, "fields": {"action_time": "2024-07-08T13:16:27.430Z", "user": 1, "content_type": 1, "object_id": "5", "object_repr": "Coag object (5)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx hold b c\", \"Nx restart a c\", \"Db hold b c\", \"Db restart a c\", \"Ap hold b c\", \"Ap restart a c\"]}}]"}}, {"model": "admin.logentry", "pk": 64, "fields": {"action_time": "2024-07-08T13:16:33.472Z", "user": 1, "content_type": 1, "object_id": "6", "object_repr": "Coag object (6)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 65, "fields": {"action_time": "2024-07-08T13:16:55.625Z", "user": 1, "content_type": 1, "object_id": "7", "object_repr": "Coag object (7)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx hold b p\", \"Nx restart a p\", \"Nx hold b c\", \"Nx restart a c\", \"Db hold b p\", \"Db restart a p\", \"Db hold b c\", \"Db restart a c\", \"Ap hold b p\", \"Ap restart a p\", \"Ap hold b c\", \"Ap restart a c\"]}}]"}}, {"model": "admin.logentry", "pk": 66, "fields": {"action_time": "2024-07-08T13:17:07.125Z", "user": 1, "content_type": 1, "object_id": "8", "object_repr": "Coag object (8)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx hold b c\", \"Db hold b c\", \"Ap hold b c\"]}}]"}}, {"model": "admin.logentry", "pk": 67, "fields": {"action_time": "2024-07-08T13:17:12.734Z", "user": 1, "content_type": 1, "object_id": "8", "object_repr": "Coag object (8)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 68, "fields": {"action_time": "2024-07-08T13:17:21.958Z", "user": 1, "content_type": 1, "object_id": "9", "object_repr": "Coag object (9)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 69, "fields": {"action_time": "2024-07-08T13:17:34.828Z", "user": 1, "content_type": 1, "object_id": "10", "object_repr": "Coag object (10)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 70, "fields": {"action_time": "2024-07-08T13:17:39.764Z", "user": 1, "content_type": 1, "object_id": "11", "object_repr": "Coag object (11)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 71, "fields": {"action_time": "2024-07-08T13:18:00.396Z", "user": 1, "content_type": 1, "object_id": "13", "object_repr": "Coag object (13)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx hold b p\", \"Nx restart a p\", \"Nx hold b c\", \"Nx restart a c\", \"Db hold b p\", \"Db restart a p\", \"Db hold b c\", \"Db restart a c\", \"Ap hold b p\", \"Ap restart a p\", \"Ap hold b c\", \"Ap restart a c\"]}}]"}}, {"model": "admin.logentry", "pk": 72, "fields": {"action_time": "2024-07-08T13:18:10.799Z", "user": 1, "content_type": 1, "object_id": "14", "object_repr": "Coag object (14)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 73, "fields": {"action_time": "2024-07-08T13:18:15.329Z", "user": 1, "content_type": 1, "object_id": "14", "object_repr": "Coag object (14)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 74, "fields": {"action_time": "2024-07-08T13:18:26.000Z", "user": 1, "content_type": 1, "object_id": "15", "object_repr": "Coag object (15)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Db hold b c\", \"Ap hold b c\"]}}]"}}, {"model": "admin.logentry", "pk": 75, "fields": {"action_time": "2024-07-08T13:18:32.163Z", "user": 1, "content_type": 1, "object_id": "15", "object_repr": "Coag object (15)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 76, "fields": {"action_time": "2024-07-08T13:18:37.122Z", "user": 1, "content_type": 1, "object_id": "16", "object_repr": "Coag object (16)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 77, "fields": {"action_time": "2024-07-08T13:18:41.203Z", "user": 1, "content_type": 1, "object_id": "17", "object_repr": "Coag object (17)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 78, "fields": {"action_time": "2024-07-08T13:18:47.434Z", "user": 1, "content_type": 1, "object_id": "18", "object_repr": "Coag object (18)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 79, "fields": {"action_time": "2024-07-08T13:18:52.919Z", "user": 1, "content_type": 1, "object_id": "19", "object_repr": "Coag object (19)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 80, "fields": {"action_time": "2024-07-08T13:18:56.503Z", "user": 1, "content_type": 1, "object_id": "20", "object_repr": "Coag object (20)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 81, "fields": {"action_time": "2024-07-10T13:01:04.185Z", "user": 1, "content_type": 1, "object_id": "11", "object_repr": "Coag object (11)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 82, "fields": {"action_time": "2024-07-10T13:01:20.617Z", "user": 1, "content_type": 1, "object_id": "12", "object_repr": "Coag object (12)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 83, "fields": {"action_time": "2024-07-10T13:01:58.306Z", "user": 1, "content_type": 1, "object_id": "16", "object_repr": "Coag object (16)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 84, "fields": {"action_time": "2024-07-10T13:02:19.352Z", "user": 1, "content_type": 1, "object_id": "17", "object_repr": "Coag object (17)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 85, "fields": {"action_time": "2024-07-10T13:02:39.058Z", "user": 1, "content_type": 1, "object_id": "18", "object_repr": "Coag object (18)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 86, "fields": {"action_time": "2024-07-10T13:03:00.577Z", "user": 1, "content_type": 1, "object_id": "21", "object_repr": "Coag object (21)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 87, "fields": {"action_time": "2024-07-10T13:03:23.751Z", "user": 1, "content_type": 1, "object_id": "22", "object_repr": "Coag object (22)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 88, "fields": {"action_time": "2024-07-10T13:03:47.527Z", "user": 1, "content_type": 1, "object_id": "23", "object_repr": "Coag object (23)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 89, "fields": {"action_time": "2024-07-10T13:04:44.981Z", "user": 1, "content_type": 11, "object_id": "14", "object_repr": "문 14. 49 세 남자 환자가 교통사고로 인한 외상성 경막외 출혈로 전신마취하에 개두술을\r\n시행 예정이다. 모든 환자 감시장치 소견은 정상이었으며 수술실 입실 후 측정한\r\n맥박산소포화도는 98%로 측정되었다. 흡입산소농도 50%에서 시행한 동맥혈 검사는 pH \r\n7.402, PaCO2 42 mmHg, PaO2 160 mmHg, BE -1.01 mmol/L", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Image\"]}}]"}}, {"model": "admin.logentry", "pk": 90, "fields": {"action_time": "2024-07-10T13:05:31.771Z", "user": 1, "content_type": 11, "object_id": "14", "object_repr": "문 14. 49 세 남자 환자가 교통사고로 인한 외상성 경막외 출혈로 전신마취하에 개두술을\r\n시행 예정이다. 모든 환자 감시장치 소견은 정상이었으며 수술실 입실 후 측정한\r\n맥박산소포화도는 98%로 측정되었다. 흡입산소농도 50%에서 시행한 동맥혈 검사는 pH \r\n7.402, PaCO2 42 mmHg, PaO2 160 mmHg, BE -1.01 mmol/L", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Image\"]}}]"}}, {"model": "admin.logentry", "pk": 91, "fields": {"action_time": "2024-07-10T13:09:41.771Z", "user": 1, "content_type": 1, "object_id": "16", "object_repr": "Coag object (16)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 92, "fields": {"action_time": "2024-07-10T13:09:51.534Z", "user": 1, "content_type": 1, "object_id": "17", "object_repr": "Coag object (17)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 93, "fields": {"action_time": "2024-07-10T13:10:09.815Z", "user": 1, "content_type": 1, "object_id": "23", "object_repr": "Coag object (23)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "auth.permission", "pk": 1, "fields": {"name": "Can add coag", "content_type": 1, "codename": "add_coag"}}, {"model": "auth.permission", "pk": 2, "fields": {"name": "Can change coag", "content_type": 1, "codename": "change_coag"}}, {"model": "auth.permission", "pk": 3, "fields": {"name": "Can delete coag", "content_type": 1, "codename": "delete_coag"}}, {"model": "auth.permission", "pk": 4, "fields": {"name": "Can view coag", "content_type": 1, "codename": "view_coag"}}, {"model": "auth.permission", "pk": 5, "fields": {"name": "Can add neuraxial", "content_type": 2, "codename": "add_neuraxial"}}, {"model": "auth.permission", "pk": 6, "fields": {"name": "Can change neuraxial", "content_type": 2, "codename": "change_neuraxial"}}, {"model": "auth.permission", "pk": 7, "fields": {"name": "Can delete neuraxial", "content_type": 2, "codename": "delete_neuraxial"}}, {"model": "auth.permission", "pk": 8, "fields": {"name": "Can view neuraxial", "content_type": 2, "codename": "view_neuraxial"}}, {"model": "auth.permission", "pk": 9, "fields": {"name": "Can add log entry", "content_type": 3, "codename": "add_logentry"}}, {"model": "auth.permission", "pk": 10, "fields": {"name": "Can change log entry", "content_type": 3, "codename": "change_logentry"}}, {"model": "auth.permission", "pk": 11, "fields": {"name": "Can delete log entry", "content_type": 3, "codename": "delete_logentry"}}, {"model": "auth.permission", "pk": 12, "fields": {"name": "Can view log entry", "content_type": 3, "codename": "view_logentry"}}, {"model": "auth.permission", "pk": 13, "fields": {"name": "Can add permission", "content_type": 4, "codename": "add_permission"}}, {"model": "auth.permission", "pk": 14, "fields": {"name": "Can change permission", "content_type": 4, "codename": "change_permission"}}, {"model": "auth.permission", "pk": 15, "fields": {"name": "Can delete permission", "content_type": 4, "codename": "delete_permission"}}, {"model": "auth.permission", "pk": 16, "fields": {"name": "Can view permission", "content_type": 4, "codename": "view_permission"}}, {"model": "auth.permission", "pk": 17, "fields": {"name": "Can add group", "content_type": 5, "codename": "add_group"}}, {"model": "auth.permission", "pk": 18, "fields": {"name": "Can change group", "content_type": 5, "codename": "change_group"}}, {"model": "auth.permission", "pk": 19, "fields": {"name": "Can delete group", "content_type": 5, "codename": "delete_group"}}, {"model": "auth.permission", "pk": 20, "fields": {"name": "Can view group", "content_type": 5, "codename": "view_group"}}, {"model": "auth.permission", "pk": 21, "fields": {"name": "Can add user", "content_type": 6, "codename": "add_user"}}, {"model": "auth.permission", "pk": 22, "fields": {"name": "Can change user", "content_type": 6, "codename": "change_user"}}, {"model": "auth.permission", "pk": 23, "fields": {"name": "Can delete user", "content_type": 6, "codename": "delete_user"}}, {"model": "auth.permission", "pk": 24, "fields": {"name": "Can view user", "content_type": 6, "codename": "view_user"}}, {"model": "auth.permission", "pk": 25, "fields": {"name": "Can add content type", "content_type": 7, "codename": "add_contenttype"}}, {"model": "auth.permission", "pk": 26, "fields": {"name": "Can change content type", "content_type": 7, "codename": "change_contenttype"}}, {"model": "auth.permission", "pk": 27, "fields": {"name": "Can delete content type", "content_type": 7, "codename": "delete_contenttype"}}, {"model": "auth.permission", "pk": 28, "fields": {"name": "Can view content type", "content_type": 7, "codename": "view_contenttype"}}, {"model": "auth.permission", "pk": 29, "fields": {"name": "Can add session", "content_type": 8, "codename": "add_session"}}, {"model": "auth.permission", "pk": 30, "fields": {"name": "Can change session", "content_type": 8, "codename": "change_session"}}, {"model": "auth.permission", "pk": 31, "fields": {"name": "Can delete session", "content_type": 8, "codename": "delete_session"}}, {"model": "auth.permission", "pk": 32, "fields": {"name": "Can view session", "content_type": 8, "codename": "view_session"}}, {"model": "auth.permission", "pk": 33, "fields": {"name": "Can add board", "content_type": 9, "codename": "add_board"}}, {"model": "auth.permission", "pk": 34, "fields": {"name": "Can change board", "content_type": 9, "codename": "change_board"}}, {"model": "auth.permission", "pk": 35, "fields": {"name": "Can delete board", "content_type": 9, "codename": "delete_board"}}, {"model": "auth.permission", "pk": 36, "fields": {"name": "Can view board", "content_type": 9, "codename": "view_board"}}, {"model": "auth.permission", "pk": 37, "fields": {"name": "Can add exam", "content_type": 10, "codename": "add_exam"}}, {"model": "auth.permission", "pk": 38, "fields": {"name": "Can change exam", "content_type": 10, "codename": "change_exam"}}, {"model": "auth.permission", "pk": 39, "fields": {"name": "Can delete exam", "content_type": 10, "codename": "delete_exam"}}, {"model": "auth.permission", "pk": 40, "fields": {"name": "Can view exam", "content_type": 10, "codename": "view_exam"}}, {"model": "auth.permission", "pk": 41, "fields": {"name": "Can add question", "content_type": 11, "codename": "add_question"}}, {"model": "auth.permission", "pk": 42, "fields": {"name": "Can change question", "content_type": 11, "codename": "change_question"}}, {"model": "auth.permission", "pk": 43, "fields": {"name": "Can delete question", "content_type": 11, "codename": "delete_question"}}, {"model": "auth.permission", "pk": 44, "fields": {"name": "Can view question", "content_type": 11, "codename": "view_question"}}, {"model": "auth.user", "pk": 1, "fields": {"password": "pbkdf2_sha256$720000$FjTNNqtynRriPsdL6lg9ek$Nliuzp8mq0mp3PWNXiCYMPHk+yKLFJrpysGUwkMGM48=", "last_login": "2024-07-02T03:18:17.212Z", "is_superuser": true, "username": "admin", "first_name": "", "last_name": "", "email": "escapebaek@gmail.com", "is_staff": true, "is_active": true, "date_joined": "2024-06-24T06:28:42.868Z", "groups": [], "user_permissions": []}}, {"model": "auth.user", "pk": 3, "fields": {"password": "pbkdf2_sha256$720000$zema9bnqinWeCv0TlzFMrS$KAaEMbT3NuZcN0gB24zvMSpKg68dsBqJIpIU3Mp1ol8=", "last_login": "2024-06-26T09:15:45.813Z", "is_superuser": false, "username": "test", "first_name": "", "last_name": "", "email": "test@test.com", "is_staff": false, "is_active": true, "date_joined": "2024-06-26T05:52:16.728Z", "groups": [], "user_permissions": []}}, {"model": "contenttypes.contenttype", "pk": 1, "fields": {"app_label": "coag", "model": "coag"}}, {"model": "contenttypes.contenttype", "pk": 2, "fields": {"app_label": "coag", "model": "neuraxial"}}, {"model": "contenttypes.contenttype", "pk": 3, "fields": {"app_label": "admin", "model": "logentry"}}, {"model": "contenttypes.contenttype", "pk": 4, "fields": {"app_label": "auth", "model": "permission"}}, {"model": "contenttypes.contenttype", "pk": 5, "fields": {"app_label": "auth", "model": "group"}}, {"model": "contenttypes.contenttype", "pk": 6, "fields": {"app_label": "auth", "model": "user"}}, {"model": "contenttypes.contenttype", "pk": 7, "fields": {"app_label": "contenttypes", "model": "contenttype"}}, {"model": "contenttypes.contenttype", "pk": 8, "fields": {"app_label": "sessions", "model": "session"}}, {"model": "contenttypes.contenttype", "pk": 9, "fields": {"app_label": "board", "model": "board"}}, {"model": "contenttypes.contenttype", "pk": 10, "fields": {"app_label": "exam", "model": "exam"}}, {"model": "contenttypes.contenttype", "pk": 11, "fields": {"app_label": "exam", "model": "question"}}, {"model": "sessions.session", "pk": "8atvc4i7rsjl9etu1w9np804puh70fe6", "fields": {"session_data": ".eJxVjEEOwiAURO_C2hCgQMWle89AgPlI1UBS2pXx7rZJF7qceW_mzXxYl-LXTrOfwC5MstNvF0N6Ut0BHqHeG0-tLvMU-a7wg3Z-a6DX9XD_DkroZVvrcYA0MBjg4IazS9kISoCwVtgtxJgpalLJKgOQsGZ0WWpkoQAt2OcL-Vc4mA:1sOU25:j9VsZH8H2ZlOgkzNajYVh4aZdfMD8UBvnZCh6OxRzyY", "expire_date": "2024-07-16T03:18:17.215Z"}}, {"model": "sessions.session", "pk": "inyot7tkch7xjmdeurigy4uvqstgdsic", "fields": {"session_data": ".eJxVjEEOwiAURO_C2hCgQMWle89AgPlI1UBS2pXx7rZJF7qceW_mzXxYl-LXTrOfwC5MstNvF0N6Ut0BHqHeG0-tLvMU-a7wg3Z-a6DX9XD_DkroZVvrcYA0MBjg4IazS9kISoCwVtgtxJgpalLJKgOQsGZ0WWpkoQAt2OcL-Vc4mA:1sNliG:exB_GDb6UZJErp9Up97MGl3eD-tz2cW2vG5jCY9n2GE", "expire_date": "2024-07-14T03:58:52.977Z"}}]